Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ANG-3777 in Hemodialysis
NCT04958187Phase 1Unknown
- Sponsor
- Angion Biomedica Corp.
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of terevalefim in kidney failure (ESRD), sponsored by Angion Biomedica Corp. Primary endpoints: Time to Maximum Concentration at Day 2, Maximum Plasma Concentration at Day 2 and 1 more. Status: unknown.
02
Drugs
terevalefim
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT04958187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958187.